drip vitals - semaglutide miami/ ozempic/ tirzepatide/ mounjaro weight loss vs Tirzepatide: Which GLP-1 Wins for Loss? F.D.A. Approves New Obesity Drug

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus (under the brand name Mounjaro) and chronic weight management (under the brand name Zepbound)

References: About The Author Dr

Drug Interactions Cytochrome P450-Metabolized Drugs Co-administration of tesamorelin with simvastatin, a sensitive CYP3A substrate, showed that tesamorelin had no significant impact on the pharmacokinetics profiles of simvastatin in healthy subjects

Begin Wegovy first, allow 48 weeks for adaptation, then discuss Lipo C with your doctor if needed

JCI Insight [Internet]